Climb Bio, Inc. — Form 8-K
Filed November 5, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Climb Bio, a clinical-stage biotech with market cap ~$44.8M, reported Q3 2026 cash position of $227.6M (51% of market value) with runway into H2 2028. Key developments: CLYM116 Phase 1 in healthy volunteers showed 90% free APRIL suppression and ~70% Gd-IgA1 reduction at 12 weeks, supporting every-12-week dosing; NAVIGATE-2 Phase 2 in IgA nephropathy initiated with initial data expected H1 2027. Budoprutug Phase 2 in primary membranous nephropathy (PrisMN) showed 200 mg dose achieved B-cell depletion, PLA2R antibody reduction, and immunologic remission at 12 weeks; Phase 1b in SLE (17 patients) demonstrated dose-dependent B-cell depletion and favorable safety; additional ITP Phase 1b data expected December 2026. Q3 R&D expenses $11.0M vs $9.1M prior year; net loss $14.6M vs $12.9M prior year.
Why this rating
Strong cash position funds programs 18+ months; multiple Phase 2/Phase 3-enabling datasets support pipeline momentum and near-term value catalysts.
Tradability signal
NO TRADE
No trade: positive news with only -2.9% moved so far — good news prices in within seconds and long-side continuation has shown no measured edge (this cell: -0.53% over 4 hrs, n=325). (Filing arrived outside market hours — evaluated at the next open with a live quote.)
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
before filing · preread $9.32 ▲ 3.21% | at our read · unknown $9.03 | +10 min · unknown $8.99 ▼ 0.44% | +30 min · unknown $8.89 ▼ 1.50% | +1 hr · unknown $8.82 ▼ 2.27% | +4 hrs · unknown $9.00 ▼ 0.33% |
The stock had already moved -3.11% between hitting EDGAR and our read finishing — deltas above are measured from our read.
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from November 5, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.